Publication of impact on health-related quality of life from 3 year data with vosoritide. These data suggest that after 3 years of treatment, vosoritide demonstrates a…
Read MoreDespite the recognized expertise of pediatric endocrinologists, children with skeletal dysplasias have not been consistently managed by these physicians. Growth-altering treatments have broadened the role of…
Read MoreAchondroplasia growth charts included in this article. Achondroplasia is the most common genetic skeletal disorder causing disproportionate short stature/dwarfism. Common additionalfeatures include spinal stenosis, midface retrusion,…
Read More